by The plasmid DNA manufacturing process involves the isolation or manipulation of plasmid DNA through various techniques including bacterial fermentation, midiprep or digestion techniques. Plasmid DNA is used in therapeutic applications such as gene and DNA vaccines, gene therapy and stem cell therapy. Gene therapy leverages the functional properties of genes to produce therapeutic proteins and treat or prevent diseases. The significant use of gene therapy in treating chronic diseases like cancer, cardiovascular diseases and neurological disorders is expected to drive the demand for plasmids.
The global plasmid DNA manufacturing market is estimated to be valued at US$ 901.2 billion in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The opportunity presented by gene therapy for treating various diseases as highlighted in the heading is one of the key drivers propelling the growth of the plasmid DNA manufacturing market. Gene therapy is a promising therapy for treating several life-threatening diseases and involves the delivery of therapeutic nucleic acids, typically plasmid DNA, to enable or restore functional genes. Plasmid DNA serves as an essential component for administering gene therapy. Additionally, the rising R&D investments by pharmaceutical companies in plasmid-based therapeutics is also fueling the market growth. Large pharmaceutical players are collaborating with plasmid manufacturers to boost their R&D capabilities and pipeline of plasmid-based drugs. For instance, Aldevron partnered with Novartis to develop next-generation plasmid DNA for gene and cell therapies. Furthermore, advancements in gene therapy development coupled with the increasing translational research activities are broadening the scope of gene therapy and thereby expanding the applications of plasmids. The market is thus expected to exhibit lucrative growth over the forecast period driven by these factors.
Segment Analysis
The plasmid DNA manufacturing market is dominated by the therapeutic plasmid DNA segment. Therapeutic plasmid DNA is widely used in gene therapy to treat diseases like cancer, cardiovascular disorders, and other genetic diseases. It helps in repairing mutated genes or introducing new genes to compensate for abnormal genes. Compared to other segments like vaccine plasmid DNA and recombinant plasmid DNA, the demand for therapeutic plasmid DNA is higher due to its increasing application in developing novel gene therapies for various life-threatening diseases.
PEST Analysis
Political: Governments across the globe are supporting the development of advanced gene therapies through funding and favorable regulations. For instance, the FDA has approved many gene therapy products to treat rare diseases.
Economic: The rising incidence of genetic disorders and cancer is driving the need for effective treatments like gene therapy. This is positively impacting the growth of the plasmid DNA manufacturing market.
Social: With growing awareness, people are inclined toward advanced therapies like gene therapy for the treatment of previously untreatable conditions. This is increasing the demand for plasmid DNA.
Technological: Companies are focusing on developing innovative manufacturing technologies like continuous manufacturing platforms to reduce production costs and improve yield for plasmid DNA production.
Key Takeaways
The global plasmid DNA manufacturing market is expected to witness high growth over the forecast period owing to the increasing development and demand for gene therapy products. Global Plasmid DNA Manufacturing Market Size is estimated to be valued at US$ 901.2 billion in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030.
Regional analysis: North America dominates the global market and is expected to maintain its lead position during the forecast period. This can be attributed to the rising gene therapy treatment approvals in the region and presence of major market players.
Key players operating in the plasmid DNA manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc. Key players are focused on enhancing their manufacturing capabilities and capacities to meet the growing demand for plasmid DNA.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
